Aktis Oncology

Aktis's lead program targets Nectin-4, a cell adhesion molecule overexpressed in bladder, breast, and lung cancers. The compound uses an engineered miniprotein to deliver an alpha-emitting radioisotope directly to tumor cells. This design enables deep tumor penetration and rapid systemic clearance, aiming to maximize anti-tumor activity while sparing healthy tissue from radiation exposure.

Aktis has raised approximately $313 million in total disclosed financing through a combination of venture rounds and strategic partnerships. The $72 million Series A closed in 2021, led by MPM Capital and Vida Ventures. An additional $175 million Series B closed in August 2024, co-led by RA Capital Management and RTW Investments, with participation from Bristol Myers Squibb, Novartis Venture Fund, and other crossover investors. Eli Lilly also made a $60 million upfront payment as part of a broader collaboration (per the firm, 2022).

Matthew Roden serves as Chief Executive Officer and President, having previously founded the company within MPM Capital's incubator. The board includes representatives from key venture investors MPM Capital, Vida Ventures, RA Capital Management, and RTW Investments, reflecting a governance structure typical of syndicated venture-backed biotechs where major financing leads hold board seats and co-steer strategic financing and partnership decisions.

Traditional antibody-drug conjugates (ADCs) use large antibodies that can exhibit slow tumor penetration and prolonged circulation in healthy tissues. Aktis uses engineered miniproteins—smaller, more compact binders—that penetrate solid tumors more deeply and clear from the bloodstream within hours. This rapid clearance reduces off-target radiation exposure, a key differentiator from both ADCs and earlier-generation radiopharmaceuticals that use antibody-based targeting.

Aktis's pipeline remains in preclinical and IND-enabling stages as of mid-2024. The Series B financing announced in August 2024 is explicitly intended to advance the Nectin-4 program toward an investigational new drug application and subsequent Phase 1 clinical trials. No specific IND filing date has been publicly disclosed.

Announced in 2022, the collaboration grants Eli Lilly exclusive ex-U.S. rights to certain Aktis oncology programs in exchange for a $60 million upfront payment and an undisclosed equity investment. Aktis retains full U.S. commercial rights and operational control over its pipeline, while Lilly handles regulatory and commercial activities outside the United States. The deal also includes downstream milestones and royalties.

Aktis's foundational radiopharmaceutical technology originates from laboratories at Memorial Sloan Kettering Cancer Center and the University of Massachusetts Medical School. The company was formed to translate academic research on engineered miniprotein binders into clinical-stage oncology candidates, with a patent portfolio covering both the targeting ligands and the radiochemistry methods for attaching alpha-emitting isotopes.